

PROTEIN DESIGN LABS INC/DE
Form 8-K
December 24, 2003

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 22, 2003**

PROTEIN DESIGN LABS, INC.
(Exact name of registrant as specified in its charter)

Delaware		000-19756		94-3023969
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
34801 Campus Drive				
Fremont, California 94555				
(Address of principal executive offices)				(Zip Code)
Registrant's telephone number, including area code: (510) 574-1400				
Not Applicable				
(Former name or former address, if changed since last report)				

Item 5. Other Events

On December 22, 2003, Protein Design Labs, Inc. (PDL) issued a press release announcing that PDL and Genentech concluded a definitive agreement which resolves their dispute relating to PDL 's antibody humanization patents and certain of Genentech 's humanized antibodies. A copy of PDL 's press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7. Financial Statements and Exhibits

(c) Exhibits

99.1 Press Release dated December 22, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTEIN DESIGN LABS, INC.

Date: December 24, 2003

By: */s/ Sergio Garcia-Rodriguez*
Sergio Garcia-Rodriguez
Vice President, Legal, General Counsel and
Assistant Secretary

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated December 22, 2003.
